DOCSLIB.ORG

Management of Chronic Anterior Uveitis Relapses: Efficacy of Oral Phospholipidic Curcumin Treatment. Long-Term Follow-Up

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Chronic Anterior Uveitis Relapses: Efficacy of Oral Phospholipidic Curcumin Treatment. Long-Term Follow-Up Clinical Ophthalmology Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up Pia Allegri1 Abstract: Curcumin has been successfully applied to treat inflammatory conditions in Antonio Mastromarino1 experimental research and in clinical trials. The purpose of our study is to evaluate the efficacy Piergiorgio Neri2 of an adjunctive-to-traditional treatment with Norflo tablets (curcumin-phosphatidylcholine complex; Meriva) administered twice a day in recurrent anterior uveitis of different etiologies. The 1Uveitis Center, Ophthalmological Department of Lavagna Hospital, study group consisted of 106 patients who completed a 12-month follow-up therapeutic period. Genova, Italy; 2Uveitis Unit, The We divided the patients into three main groups of different uveitis origin: group 1 (autoimmune Eye Clinic, Azienda Ospedaliero- uveitis), group 2 (herpetic uveitis), and group 3 (different etiologies of uveitis). The primary Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy end point of our work was the evaluation of relapse frequency in all treated patients, before and after Norflo treatment, followed by the number of relapses in the three etiological groups. Wilcoxon signed-rank test showed a P , 0.001 in all groups. The secondary end points were the evaluation of relapse severity and of the overall quality of life. The results showed that Norflo was well tolerated and could reduce eye discomfort symptoms and signs after a few weeks of treatment in more than 80% of patients. In conclusion, our study is the first to report the potential therapeutic role of curcumin and its efficacy in eye relapsing diseases, such as anterior uveitis, and points out other promising curcumin-related benefits in eye inflammatory and degenerative conditions, such as dry eye, maculopathy, glaucoma, and diabetic retinopathy. Keywords: curcumin, anterior recurrent uveitis, phosphatidylcholine-bound-curcumin (Meriva) Introduction In recent clinical studies, curcumin showed its antioxidant, chemopreventive, and anti- inflammatory activity in acute and chronic inflammation both in clinical practice (used in neurodegenerative, pulmonary, metabolic, autoimmune, and neoplastic diseases) and in experimental models. In the latter case, eg, Mohan et al showed that curcuminoids target fibroblast growth factor-2 and inhibit expression of gelatinase B in the angiogenic process by using the cultured corneal cells of a transgenic mouse.9 In an experimental dry eye model, Chen et al investigated the anti-inflammatory effects of curcumin in curcumin pretreated cultured corneal epithelial cells exposed to hyperosmotic condi- tions.29 Kumar et al30 reported that curcumin feeding to rats with chemical-induced hyperglycemia can reduce oxidative stress that is the main cause of progression of 1–12 Correspondence: Pia Allegri cataract. The beneficial effects of this drug appear now to be related to the effect on Uveitis Center Head, Ophthalmological upregulation of peroxisome proliferator-activated receptor-γ (PPAR-γ), which is a ligand- Department of Lavagna Hospital, inducible transcription factor involved mainly in controlling inflammation in peripheral Corso Valparaiso 96/3, Chiavari 16043, Genova, Italy organs. Activation of PPAR-γ has been shown to control the response in microglial cells Tel +39 0185 329626 and limit inflammation.13–17 Curcumin has poor systemic availability, but recent stud- Fax +39 0185 329627 Email [email protected] ies have shown that the phosphatidylcholine formulation (Meriva®) increases its oral submit your manuscript | www.dovepress.com Clinical Ophthalmology 2010:4 1201–1206 1201 Dovepress © 2010 Allegri et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article DOI: 10.2147/OPTH.S13271 which permits unrestricted noncommercial use, provided the original work is properly cited. Allegri et al Dovepress bioavailability.18–21 Yadav et al showed the inhibitory effect of 180, and 360 days. The evaluation of the results at the end of curcumin on cell proliferation and production of cytokines, the follow-up period was carried out by comparing the results which are the main phenomena involved in inflammation.12 before and after 1 year of follow-up in patients presenting Many studies have been conducted on curcumin, but only Lal 4, 3, 2, or 1 relapses per year. We also studied the percentage et al have shown the efficacy of curcumin on chronic anterior of satisfaction and tolerance to additional therapy by means uveitis.22 Based on the previous data, we report our experi- of a detailed questionnaire (included into the clinical record ence in patients suffering from relapsing anterior uveitis of sheet) developed with the purpose of analyzing the patient different etiologies. tolerance and compliance to treatment at the end of 1 year Norflo therapy. Material and methods A total of 122 patients (68 men and 54 women) with recurrent Statistical analysis anterior uveitis (RAU) were enrolled in the study. The age Frequency of total relapses, before and after 1 year of Norflo of the patients ranged from 21 to 68 (mean, 37 ± 4.7). All therapy, was assessed with Wilcoxon signed-rank test. patients signed a written informed consent before entering into the study in accordance with the Helsinki International Results Treaty criteria. The patients included in the study were We compared the results, before and after the treatment with selected from those followed in our tertiary referral uveitis Norflo, of the total number of patients with relapses and the centre (Lavagna Hospital, Genova, Italy) in a previous period number of total relapses. of about 2 years (mean ± 3 months) and affected by RAU with As shown in Figure 1A, 106 patients (corresponding 1–4 relapses in a year. The RAU diagnosis was made by two to the global number of patients included into the study) different ophthalmologists with more experience on uveitis had relapses before the treatment with Norflo, and only and was based on standard clinical criteria of International 19 patients had relapses after the treatment with Norflo. Uveitis Study Group (IUSG).23 Ophthalmological examina- As shown in Figure 1B, there were in total 275 relapses 1 tion included each time: slit-lamp examination with IUSG year before the treatment with Norflo and only 36 relapses at grading of anterior segment cells and flare (from 0 to +4 ), the end of the 12-month follow-up period, after the treatment Early Treatment Diabetic Retinopathy Study (ETDRS) visual with Norflo (88% of improvement). acuity measurement, intraocular pressure measurement, and Tables 1 and 2 show the detailed results before and after fundus examination with Volk + 90 lens. We developed a Norflo treatment in all treated patients, respectively. Thetab le specific medical record in which, at each check-up visit, we specifies the number of patients with 4, 3, 2, or 1 relapses per registered the findings for each patient included in the study. year and the total number of relapses per year. Recurrent anterior bilateral or unilateral uveitis etiology For instance, in Table 1 (before the treatment with Norflo) was mainly of autoimmune origin (56 patients), followed six patients had four relapses per year, which means a total by RAU of herpetic origin (28 patients), and of different or number of 24 relapses per year. In Table 2 (after the treatment unknown origin (22 patients). All the patients received an with Norflo) we can see that no patients had four relapses per orally administered product, Norflo® (Eye Pharma Co, Italy) year, with no relapses in 1 year. Therefore, the six patients containing 600 mg of Meriva (Indena, Milano, Italy) in each who had four relapses per year before the treatment had zero tablet, at the dosage of two tablets/day during the follow-up relapses after Norflo additional therapy. In the second row period. An ongoing therapy with systemic drugs (steroids, of the same tables, 58 patients had three relapses per year, immune-suppressants, antiherpetic, and antitoxoplasmic which means a total of 174 relapses before treatment, and drugs) or eye drops (steroids, mydriatics, and cycloplegics only four patients had three relapses per year, which means nonsteroidal anti-inflammatory drug) was maintained, and a total of 12 relapses per year after treatment. Norflo tablets were added as an adjunctive treatment. The As shown in the tables, the results were highly significant therapy was only administered to patients who had frequent with the Wilcoxon signed-rank test at a P , 0.001 in all relapses in the last 2 years of follow-up and was started at groups. There was also an improvement in symptoms the time of a relapse. The follow-up period varied from 12 and signs associated with relapses after Norflo treatment, to 18 months (mean ± 3 months), and 106 patients (61 men including ocular pain, blurring of vision, pericorneal and 45 women) completed the study. All patients underwent hyperemia and aqueous or vitreous cells, and flare in 42% complete ophthalmological examination at 0, 7–15, 30, 90, of patients. Only seven patients worsened, and they required 1202 submit your manuscript | www.dovepress.com Clinical Ophthalmology 2010:4 Dovepress Dovepress Management of chronic anterior uveitis relapses AB300 120 250 100 200 80 60 150 40 100 20 50 0 0 106 19 275 36 Figure 1 A) Total number of patients with relapses before and after Norflo therapy.B ) Total relapse number before and after Norflo therapy. Note: Wilcoxon signed-rank test: P , 0.001. subtenon injections of steroids. Among the first 128 patients degeneration, retinal ischemia, and diabetic retinopathy) selected, only one subject had to interrupt therapy because are now considered from an inflammatory point of view. of gastric intolerance related to reflux esophagitis. Fifteen Therefore, the treatment of inflammation could represent an patients dropped out of the study because of noncompliance important target to manage ocular diseases. Based on these with therapy or with follow-up visits.
Load more

Recommended publications
  • Differentiate Red Eye Disorders
    Introduction DIFFERENTIATE RED EYE DISORDERS • Needs immediate treatment • Needs treatment within a few days • Does not require treatment Introduction SUBJECTIVE EYE COMPLAINTS • Decreased vision • Pain • Redness Characterize the complaint through history and exam. Introduction TYPES OF RED EYE DISORDERS • Mechanical trauma • Chemical trauma • Inflammation/infection Introduction ETIOLOGIES OF RED EYE 1. Chemical injury 2. Angle-closure glaucoma 3. Ocular foreign body 4. Corneal abrasion 5. Uveitis 6. Conjunctivitis 7. Ocular surface disease 8. Subconjunctival hemorrhage Evaluation RED EYE: POSSIBLE CAUSES • Trauma • Chemicals • Infection • Allergy • Systemic conditions Evaluation RED EYE: CAUSE AND EFFECT Symptom Cause Itching Allergy Burning Lid disorders, dry eye Foreign body sensation Foreign body, corneal abrasion Localized lid tenderness Hordeolum, chalazion Evaluation RED EYE: CAUSE AND EFFECT (Continued) Symptom Cause Deep, intense pain Corneal abrasions, scleritis, iritis, acute glaucoma, sinusitis, etc. Photophobia Corneal abrasions, iritis, acute glaucoma Halo vision Corneal edema (acute glaucoma, uveitis) Evaluation Equipment needed to evaluate red eye Evaluation Refer red eye with vision loss to ophthalmologist for evaluation Evaluation RED EYE DISORDERS: AN ANATOMIC APPROACH • Face • Adnexa – Orbital area – Lids – Ocular movements • Globe – Conjunctiva, sclera – Anterior chamber (using slit lamp if possible) – Intraocular pressure Disorders of the Ocular Adnexa Disorders of the Ocular Adnexa Hordeolum Disorders of the Ocular
    [Show full text]
  • A Description of the Clinical Features of Brimonidine- Associated Uveitis Alyssa Louie Primary Care Resident, San Francisco VA
    Drug-induced intraocular inflammation: A description of the clinical features of brimonidine- associated uveitis Alyssa Louie Primary Care Resident, San Francisco VA Abstract: A description of the clinical features, diagnostic work-up, and management of acute anterior uveitis caused by brimonidine, a widely used glaucoma medication. I. Case History a. Patient demographics: 74 year-old white male b. Chief complaint: eye pain, redness, irritation for last 2 weeks c. Ocular and medical history: i. Ocular history 1. Primary open angle glaucoma OU, diagnosed 8 years ago 2. Senile cataracts OU, not visually significant 3. Type 2 Diabetes without retinopathy OU 4. No prior history of uveitis ii. Medical history: Diabetes Mellitus Type 2 iii. No known drug allergies d. Medications i. Ocular: dorzolamide BID OU (1.5 years), brimonidine BID OU (11 months), travatan QHS OU (5.5 years) ii. Medical: metformin 500mg tab BID PO II. Pertinent Findings a. Clinical exam i. Visual acuities: OD 20/20-, OS 20/20- ii. Goldmann applanation tonometry: 13 mm Hg OD, 13 mm Hg OS iii. Anterior segment 1. OU: 3+ diffuse conjunctival injection 2. OU: central and inferior granulomatous keratic precipitates 3. OU: Grade 1+ cell, 1+ flare 4. OU: No synechiae or iris changes were present iv. Posterior segment 1. Optic Nerve a. OD: Cup-to-disc ratio 0.70H/V, distinct margins b. OS: Cup-to-disc ratio 0.75H/V, distinct margins 2. Posterior pole, periphery, vitreous: unremarkable OU b. Laboratory Studies i. ACE, Lysozyme, FTA-ABS, VDRL, HLA-B27, Rheumatoid Factor, ANA, PPD, Chest X- ray: all negative/unreactive III.
    [Show full text]
  • Reiter's Syndrome
    iMedPub JOURNALS ARCHIVES OF MEDICINE | 2009 | Vol. 1 | No. 1:1 | doi: 10.3823/032 Review Reiter's Syndrome Digna Llorente Molina, Susandra Cedeño Facultad de Ciencias Médicas 10 de Octubre. Ciudad Habana, Cuba. E-mail: [email protected] Reiter’s syndrome is a systemic disorder characterized by ocular conjunctivitis or uveitis, reactive arthritis, and urethritis manifestations. The exact cause of reactive arthritis is unknown. It occurs most commonly in men before the age of 40. It may follow an infection with Chlamydia, Campylobacter, Salmonella or Yersinia. Certain genes may make you more prone to the syndrome. The diagnosis is based on symptoms. The goal of treatment is to relieve symptoms and treat any underlying infection. Reactive arthritis may go away in 3 - 4 months, but symptoms may return over a period of several years in up to a half of those affected. The condition may become chronic. Preventing sexually transmitted diseases and gastrointestinal infection may help prevent this disease. Wash your hands and surface areas thoroughly before and after preparing food. © Archives of Medicine: Accepted after external review ■ The first description of Reiter’s syndrome was attributed in occasionally, cutaneous-mucosal lesions such as keratodermia 1916 to the re-known German physician Hans Reiter, linked to blennorrhagica and balanitis circinata; yellow papule lesions Nazi powers, and to his experiments in the concentration on the soles, palms and with less frequency on the nails, camps. In 1918, Junghanns described the first case in a young scrotum, scalp and trunk, amongst others (3), (4), (5).. The patient (1), (2). earliest manifestation of joint disorder is entesitis, normally in the Achilles tendon and in the plantar fascia of the calcaneus, Due to the syndrome’s abnormal immunological reactivity to causing shortening or lengthening of fingers and toes certain pathogens as a result of the interaction between resembling "sausage fingers and toes".
    [Show full text]
  • The Uveo-Meningeal Syndromes
    ORIGINAL ARTICLE The Uveo-Meningeal Syndromes Paul W. Brazis, MD,* Michael Stewart, MD,* and Andrew G. Lee, MD† main clinical features being a meningitis or meningoenceph- Background: The uveo-meningeal syndromes are a group of disorders that share involvement of the uvea, retina, and meninges. alitis associated with uveitis. The meningeal involvement is Review Summary: We review the clinical manifestations of uveitis often chronic and may cause cranial neuropathies, polyra- and describe the infectious, inflammatory, and neoplastic conditions diculopathies, and hydrocephalus. In this review we define associated with the uveo-meningeal syndrome. and describe the clinical manifestations of different types of Conclusions: Inflammatory or autoimmune diseases are probably uveitis and discuss the individual entities most often associ- the most common clinically recognized causes of true uveo-menin- ated with the uveo-meningeal syndrome. We review the geal syndromes. These entities often cause inflammation of various distinctive signs in specific causes for uveo-meningeal dis- tissues in the body, including ocular structures and the meninges (eg, ease and discuss our evaluation of these patients. Wegener granulomatosis, sarcoidosis, Behc¸et disease, Vogt-Koy- anagi-Harada syndrome, and acute posterior multifocal placoid pig- ment epitheliopathy). The association of an infectious uveitis with an acute or chronic meningoencephalitis is unusual but occasionally the eye examination may suggest an infectious etiology or even a The uveo-meningeal syndromes are a specific organism responsible for a meningeal syndrome. One should consider the diagnosis of primary ocular-CNS lymphoma in heterogeneous group of disorders that share patients 40 years of age or older with bilateral uveitis, especially involvement of the uvea, retina, and meninges.
    [Show full text]
  • UVEITIS Eye74 (1)
    UVEITIS Eye74 (1) Uveitis Last updated: May 9, 2019 Classification .................................................................................................................................... 1 Etiologic categories .......................................................................................................................... 2 Treatment ......................................................................................................................................... 2 Complications ................................................................................................................................... 2 COMMON UVEITIC SYNDROMES ............................................................................................................. 2 Masquerade Syndromes ................................................................................................................... 3 UVEITIS - heterogenous ocular diseases - inflammation of any component of uveal tract (iris, ciliary body, choroid). CLASSIFICATION ANTERIOR UVEITIS (most common uveitis) - localized to anterior segment - iritis and iridocyclitis. IRITIS - white cells confined solely to anterior chamber. IRIDOCYCLITIS - cellular activity also involves retrolental vitreous. etiology (most do not have underlying systemic disease): 1) idiopathic postviral syndrome (most commonly 38-60%) 2) HLA-B27 syndromes, many arthritic syndromes (≈ 17%) 3) trauma (5.7%) 4) herpes simplex, herpes zoster disease (1.9-12.4%) 5) iatrogenic (postoperative). tends to
    [Show full text]
  • Clinical Practice Guidelines: Care of the Patient with Anterior Uveitis
    OPTOMETRY: OPTOMETRIC CLINICAL THE PRIMARY EYE CARE PROFESSION PRACTICE GUIDELINE Doctors of optometry are independent primary health care providers who examine, diagnose, treat, and manage diseases and disorders of the visual system, the eye, and associated structures as well as diagnose related systemic conditions. Optometrists provide more than two-thirds of the primary eye care services in the United States. They are more widely distributed geographically than other eye care providers and are readily accessible for the delivery of eye and vision care services. There are approximately 32,000 full-time equivalent doctors of optometry currently in practice in the United States. Optometrists practice in more than 7,000 communities across the United States, serving as the sole primary eye care provider in more than 4,300 communities. Care of the Patient with The mission of the profession of optometry is to fulfill the vision and eye Anterior Uveitis care needs of the public through clinical care, research, and education, all of which enhance the quality of life. OPTOMETRIC CLINICAL PRACTICE GUIDELINE CARE OF THE PATIENT WITH ANTERIOR UVEITIS Reference Guide for Clinicians Prepared by the American Optometric Association Consensus Panel on Care of the Patient with Anterior Uveitis: Kevin L. Alexander, O.D., Ph.D., Principal Author Mitchell W. Dul, O.D., M.S. Peter A. Lalle, O.D. David E. Magnus, O.D. Bruce Onofrey, O.D. Reviewed by the AOA Clinical Guidelines Coordinating Committee: John F. Amos, O.D., M.S., Chair Kerry L. Beebe, O.D. Jerry Cavallerano, O.D., Ph.D. John Lahr, O.D.
    [Show full text]
  • Vogt-Koyanagi-Harada's Disease: Literature Review
    Artigo de Revisão Vogt-Koyanagi-Harada’s Disease: Literature Review Stephanie Gonçalves Carneiro*, Dorivaldo Lopes da Silva**, Angélica Cristina Pezzin Palheta***, Francisco Xavier Palheta Neto****, Cláudio Tobias Acatauassú Nunes*****, Thaís Oliveira Ferreira******, Talita Valleska de Campos Pereira******, Viviane Cristina dos Santos Monteiro******. * 5th year student of Medicine at Universidade do Estado do Pará (Monitor of Ophthalmology discipline). ** 5th year student of Medicine at Universidade do Estado do Pará (Monitor of Otorhinolaryngology discipline). *** Assistant teacher of ENT discipline at Universidade do Estado do Pará (Master degree in ENT by Universidade Federal do Rio de Janeiro – Doctorate student on Neuroscience by Universidade do Estado do Pará). **** Assistant teacher of ENT discipline at Universidade do Estado do Pará and Universidade Federal do Pará (Máster degree in ENT by Universidade Federal do Rio de Janeiro – Doctorate student on Neuroscience by Universidade do Estado do Pará). ***** Adjunt Professor and Head of ENT Discipline of Universidade do Estado do Pará. Visiting Professor of ENT at Universidade Federal do Pará. Master and PhD in ENT by UNIFESP). ****** Medical school student (3rd year) at Universidade do Estado do Pará. Institution: Universidade do Estado do Pará – UEPA (State Universtity). Belém / PA – Brazil. Mail address: Stephanie Gonçalves Carneiro – Travessa Rui Barbosa 619, Apto. 1301 – Belém / PA – Brazil – Zip code: 66053-260 – Telephone: (+55 91) 3242-7178 / 8123-1638 - E-mail: [email protected] Article received on December 1st, 2007. Article approved on March 16th, 2007. SUMMARY Introduction: Vogt-Koyanagi-Harada’s disease is a rare syndrome that affects tissues with melanocytes like eyes, central nervous system, skin and inner ear.
    [Show full text]
  • Central Serous Chorioretinopathy and Systemic Corticosteroids In
    Valls Pascual et al. BMC Musculoskeletal Disorders (2015) 16:378 DOI 10.1186/s12891-015-0843-4 CASE REPORT Open Access Central serous chorioretinopathy and systemic corticosteroids in rheumatic diseases: report of three cases Elia Valls Pascual1*, Lucía Martínez-Costa2 and Fernando Santander2 Abstract Background: Central serous chorioretinopathy is a disorder often related to systemic corticosteroids, drugs commonly used in rheumatologists’ clinical practice. Central serous chorioretinopathy prognosis is generally good but in some cases, it may lead to substantial loss of vision resulting in an important functional limitation for patients. It is very important to distinguish this pathology from other diseases involving retinal detachment. When central serous chorioretinopathy and uveitis coexist, it is mandatory to distinguish serous retinal detachment from a uveitis worsening, as the respective treatments can be radically different. Case presentation: We describe three cases of central serous chorioretinopathy in patients taking systemic corticosteroids due to rheumatological diseases (ankylosing spondylitis, systemic lupus erythematosus and Behçet’s disease). They were diagnosed and managed at our Multidisciplinary (Rheumatology-Ophthalmology) Uveitis Clinic. All three cases improved after corticosteroids dose tapering. Conclusion: Central serous chorioretinopathy must be kept in mind by rheumatologists as it is related to systemic corticosteroids. Keywords: Central serous chorioretinopathy, Corticosteroids, Rheumatic diseases Background
    [Show full text]
  • Vogt–Koyanagi–Harada Syndrome: a Rheumatologic Perspective
    REVIEW Vogt–Koyanagi–Harada syndrome: a rheumatologic perspective Vogt–Koyanagi–Harada (VKH) syndrome is an idiopathic systemic inflammatory disorder that affects various melanocyte-containing structures, including the eyes, meninges, inner ear and skin. It classically leads to bilateral chronic granulomatous diffuse uveitis, and its extraocular manifestation can include sensorineural hearing loss, meningitis, and cutaneous findings of vitiligo, poliosis (loss of hair pigment) and alopecia. Ethnicity/racial background and HLA genotype play a strong role in the pathogenesis of VKH syndrome. The inflammatory process is not completely understood, but recent studies have pointed to several potential autoantigen targets, and have also demonstrated the role IL-23 plays in inducing the differentiation of Th17 cells and the subsequent production of IL-17. The success in preserving the vision of VKH syndrome patients hinges on early diagnosis and aggressive treatment that includes immunomodulatory therapy, and as a result ophthalmologists are increasingly referring such patients to rheumatologists for management. It is therefore necessary for the rheumatologists to be familiar with VKH syndrome and its clinical aspects and management. Although the role of biologics in the treatment of VKH syndrome has yet to be investigated, it is possible that such treatments may prove beneficial, given what is currently known about the pathogenesis of the disease. 1 KEYWORDS: ankylosing spondylitis n chorioretinitis n HLA-DRB1*04 n IL-23 Jonathan Lipps & n immunomodulatory
    [Show full text]
  • The Trachoma Story
    Questions about the cause, the effect, the diagnosis, the infectivity, the clinical pattern, the prevention, and the treatment of trachoma are answered by an ophthalmologist from his experience and from the literature. The Trachoma Story By ARTHUR A. SINISCAL, M.D. T lIE IMPORTAN-CE of trIachoma "as a well kniowni in the civilizations of the four great sourice of hlumtiani suii ngeiiiir, as a cause of river valleys-the Ilwaicr Ho anid the Yanig(tze blinidniess, anid as a niatioinal economnic loss over Kian(r, the IJiduts anid Ganges, the Euphlrates large tracts of the world's surface is seconid to aiid Tigris, anid the :Nile-many centuries be- nlonle amllonicg the diseases of the eye, or inideed, fore Chlrist. It was recogniized anid treated in monll (liseases of all kinids." aInIcienit Egyp)t, Greece, aind Romile, as well as Tlhus Sir Stewar-t Duke-Elder, a distin- in cotuntries of Bliblical famiie. The Moslem guislhed4 B3ritislh oplhthalnmologist, assessed tra- coniquests p)robably led to its spread to Europe elhomia in a textbook published in 1934 (1). As as early as tlle eightlh cenitury (4), anid, unii- late as 1950, it was estimllated that 15 to 20 per- dooubtedly, Napoleon's campaigni to Egypt in cenit of the world populationi suffered fromi this 1798-1802 was responisible in large measure for disease (2). its dispersion aiiiongt the Euiropeanis () Throughout the wvorld, traclhoiniatologists, B3elieved to lhavle been ilitlodiUCe(l inito the oplhtlhalmuologists, sociologists, ptublic hiealtl Uniited States duIIrinig coloniial tiimes by Euri-o- workers, aid otliers are strlivingr earnestly to im- pean inuniiigrianits (6), the disease was spread prove the liealtlh anid socioecoiomic coii(litionls thromughout a cenitral belt reaching fr-omii the Al- of those afflicted witlh trachlomlla.
    [Show full text]
  • Acquired Etiologies of Lacrimal System Obstructions
    5 Acquired Etiologies of Lacrimal System Obstructions Daniel P. Schaefer Acquired obstructions of the lacrimal excretory outfl ow system will produce the symptoms of epiphora, mucopurulent discharge, pain, dacryocystitis, and even cellulitis, prompting the patient to seek the ophthalmologist for evaluation and treatment. Impaired tear outfl ow may be functional, structural, or both. The causes may be primary – those resulting from infl ammation of unknown causes that lead to occlusive fi brosis—or secondary, resulting from infections, infl amma- tion, trauma, malignancies, toxicity, or mechanical causes. Secondary acquired dacryostenosis and obstruction may result from many causes, both common and obscure. Occasionally, the precise pathogenesis of nasolacrimal duct obstruction will, despite years of investigations, be elusive. To properly evaluate and appropriately treat the patient, the ophthal- mologist must have knowledge and comprehension of the lacrimal anatomy, the lacrimal apparatus, pathophysiology, ocular and nasal relationships, ophthalmic and systemic disease process, as well as the topical and systemic medications that can affect the nasolacrimal duct system. One must be able to assess if the cause is secondary to outfl ow anomalies, hypersecretion or refl ex secretion, pseudoepiphora, eyelid malposition abnormalities, trichiasis, foreign bodies and conjunctival concretions, keratitis, tear fi lm defi ciencies or instability, dry eye syn- dromes, ocular surface abnormalities, irritation or tumors affecting the trigeminal nerve, allergy, medications, or environmental factors. Abnormalities of the lacrimal pump function can result from involu- tional changes, eyelid laxity, facial nerve paralysis, or fl oppy eyelid syndrome, all of which displace the punctum from the lacrimal lake. If the cause is secondary to obstruction of the nasolacrimal duct system, the ophthalmologist must be able to determine where the anomaly is and what the cause is, in order to provide the best treatment possible for the patient.
    [Show full text]
  • Heterochromia Iridis, Heterochromic Cyclitis, and Allied Conditions
    HETEROCHROMIA IRIDIS, HETEROCHROMIC CYCLITIS, AND ALLIED CONDITIONS. E. C. ELLETT, M.D., Memphis, Tenn. There is no doubt that there is a definite clinical and patho- logic picture or syndrome to which Harrison Butler has given the name of heterochromic cyclitis, but as the condition is by no means common, it happens that many men have not had it called to their attention. On account of its importance from a prognostic point of view, and from the fact that the condition has not impressed itself on a number of practi- tioners with whom I have spoken, it seemed to me that the report of a few more or less related cases might possess some interest. In collecting the material for this report there were several cases which presented the development of the picture as far as the onset of cataract, and two in which glaucomatous symptoms were added. There were some other cases, of great interest to me, and which presented the association of glaucoma with uveitis, which I have included in the report under the subtitle of "allied conditions." By heterochromia iridis we mean a condition in which the iris of one eye differs in color from that of the other. We do not include cases of different-colored sectors in an iris whose background is of the same color as that of the fellow-eye, but those cases in which the whole iris is of the same color, but different from that of the other eye. This condition is not rare, and it usually occurs in brunettes, and is noticed at birth or in early life, certainly before maturity, in the large majority of cases.
    [Show full text]